Adagio Medical (NASDAQ:ADGM – Get Free Report) and Mesa Laboratories (NASDAQ:MLAB – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.
Institutional and Insider Ownership
48.1% of Adagio Medical shares are owned by institutional investors. Comparatively, 90.6% of Mesa Laboratories shares are owned by institutional investors. 5.2% of Adagio Medical shares are owned by insiders. Comparatively, 4.9% of Mesa Laboratories shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Adagio Medical and Mesa Laboratories, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Adagio Medical | 1 | 0 | 1 | 0 | 2.00 |
| Mesa Laboratories | 1 | 2 | 0 | 0 | 1.67 |
Profitability
This table compares Adagio Medical and Mesa Laboratories’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Adagio Medical | N/A | -312.04% | -66.00% |
| Mesa Laboratories | 1.51% | 22.02% | 8.86% |
Valuation & Earnings
This table compares Adagio Medical and Mesa Laboratories”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Adagio Medical | $600,000.00 | 46.27 | -$25.08 million | ($1.73) | -0.72 |
| Mesa Laboratories | $240.98 million | 2.09 | -$1.97 million | $0.64 | 142.31 |
Mesa Laboratories has higher revenue and earnings than Adagio Medical. Adagio Medical is trading at a lower price-to-earnings ratio than Mesa Laboratories, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Adagio Medical has a beta of 0.04, suggesting that its share price is 96% less volatile than the S&P 500. Comparatively, Mesa Laboratories has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500.
Summary
Mesa Laboratories beats Adagio Medical on 9 of the 14 factors compared between the two stocks.
About Adagio Medical
Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. The company’s product portfolio includes iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories; vCLAS ventricular ULTC catheter; and Cryopulse atrial pulsed-field cryoablation catheter and accessories. The company is based in Laguna Hills, California.
About Mesa Laboratories
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. The Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. The Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment’s products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems, offered under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.
Receive News & Ratings for Adagio Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adagio Medical and related companies with MarketBeat.com's FREE daily email newsletter.
